Publications searcher

The science produced by our scientists is very important. In 2022, 1,629 papers were published in scientific journals with a global impact factor of over 15,000 points.

[Pertussis vaccine. Reemergence of the disease and new vaccination strategies].

PMID: 25707329
Journal: ENFERMEDADES INFECCIOSAS Y MICROBIOLOGIA CLINICA
Year: 2015
Reference: Enferm Infecc Microbiol Clin. 2015 Mar;33(3):190-6. doi: 10.1016/j.eimc.2015.02.001. Epub 2015 Feb 20.
Impact factor: 2.172
Publication type: Paper in national publication
Authors: Moraga-Llop, Fernando A, Campins-Marti, Magda et al.
DOI: 10.1016/j.eimc.2015.02.001

Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.

PMID: 25693012
Journal: NEW ENGLAND JOURNAL OF MEDICINE
Year: 2015
Reference: N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.
Impact factor: 55.873
Publication type: Paper in international publication
Authors: Grischke, E-M, Swain, Sandra M, Baselga, Jose, Kim, Sung-Bae, Ro, Jungsil, Semiglazov, Vladimir, Campone, Mario, Ciruelos, Eva, Ferrero, Jean-Marc, Schneeweiss, Andreas et al.
DOI: 10.1056/NEJMoa1413513

Perylenetetracarboxylic anhydride as a precursor of fluorescent carbon nanoonion rings.

PMID: 26135910
Journal: Nanoscale
Year: 2015
Reference: Nanoscale. 2015 Aug 7;7(29):12484-91. doi: 10.1039/c5nr02903a. Epub 2015 Jul 2.
Impact factor: 7.394
Publication type: Paper in international publication
Authors: Garcia, Hermenegildo, Alvaro, Mercedes, Manuel Victor, Victor, Herance, Jose Raul, Baldovi, Herme G et al.
DOI: 10.1039/c5nr02903a

Ph lb dose escalation study of oral pan-PI3K inhibitor buparlisib (BKM120) with oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with advanced solid tumours.

PMID: 25500057
Journal: CLINICAL CANCER RESEARCH
Year: 2015
Reference: Clin Cancer Res. 2015 Feb 15;21(4):730-8. doi: 10.1158/1078-0432.CCR-14-1814. Epub 2014 Dec 10.
Impact factor: 8.722
Publication type: Paper in international publication
Authors: Perez-Gercia, Jose, Bedard, Phillipe L, Tabernero, Josep, Janku, Filip, Wainberg, Zev A, Paz-Ares, Luis, Vansteenkiste, Johan, Van Cutsem, Eric, Le, Ngocdiep T, Carter, Kirsten et al.
DOI: 10.1158/1078-0432.CCR-14-1814

Pharmacogenomic study in patients with multiple sclerosis: Responders and nonresponders to IFN-beta.

PMID: 26445728
Journal: Neurology: Neuroimmunology & Neuroinflammation
Year: 2015
Reference: Neurol Neuroimmunol Neuroinflamm. 2015 Sep 24;2(5):e154. eCollection 2015 Oct.
Impact factor:
Publication type: Letter or abstract
Authors: Bustamante, Marta F, Morcillo-Suarez, Carlos, Malhotra, Sunny, Rio, Jordi, Leyva, Laura, Fernandez, Oscar, Zettl, Uwe K, Killestein, Joep, Brassat, David, Garcia-Merino, Juan Antonio et al.
DOI: 10.1212/NXI.0000000000000154

Pharmacokinetic and pharmacodynamic evaluation of aflibercept for the treatment of colorectal cancer.

PMID: 25988772
Journal: Expert Opinion on Drug Metabolism & Toxicology
Year: 2015
Reference: Expert Opin Drug Metab Toxicol. 2015 Jun;11(6):995-1004. doi: 10.1517/17425255.2015.1041920.
Impact factor: 2.831
Publication type: Paper in international publication
Authors: Tabernero, Josep, Sanz-Garcia, Enrique, Sauri, Tamara, Macarulla, Teresa et al.
DOI: 10.1517/17425255.2015.1041920

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-beta receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.

PMID: 25529192
Journal: INVESTIGATIONAL NEW DRUGS
Year: 2015
Reference: Invest New Drugs. 2015 Apr;33(2):357-70. doi: 10.1007/s10637-014-0192-4. Epub 2014 Dec 23.
Impact factor: 2.927
Publication type: Clinical Trials
Authors: Baselga, Jose, Lahn, Michael M, Rodon, Jordi, Carducci, Michael, Sepulveda-Sanchez, Juan M, Azaro, Analia, Calvo, Emiliano, Brana, Irene, Sicart, Elisabet, Gueorguieva, Ivelina et al.
DOI: 10.1007/s10637-014-0192-4

Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.

PMID: 25888060
Journal: CRITICAL CARE
Year: 2015
Reference: Crit Care. 2015 Feb 4;19:33. doi: 10.1186/s13054-015-0758-3.
Impact factor: 4.476
Publication type: Paper in international publication
Authors: Roberts, Jason A, Sinnollareddy, Mahipal G, Bassetti, Matteo, De Waele, Jan J, Kaukonen, Kirsi-Maija, Koulenti, Despoina, Martin, Claude, Montravers, Philippe, Rello, Jordi, Rhodes, Andrew et al.
DOI: 10.1186/s13054-015-0758-3

Pharmacological induction of mitochondrial biogenesis as a therapeutic strategy for the treatment of type 2 diabetes.

PMID: 26212547
Journal: BIOCHEMICAL PHARMACOLOGY
Year: 2015
Reference: Biochem Pharmacol. 2015 Nov 1;98(1):16-28. doi: 10.1016/j.bcp.2015.06.032. Epub 2015 Jul 23.
Impact factor: 5.009
Publication type: Paper in international publication
Authors: Zamora, Monica, Pardo, Rosario, Villena, Josep A et al.
DOI: 10.1016/j.bcp.2015.06.032

[PHARMACONUTRITION IN SEVERELY ILL PATIENT].

PMID: 26268074
Journal: Nutricion Hospitalaria
Year: 2015
Reference: Nutr Hosp. 2015 Aug 1;32(2):478-86. doi: 10.3305/nh.2015.32.2.9324.
Impact factor: 1.04
Publication type: Review in national publication
Authors: Montejo Gonzalez, Juan Carlos, Sanchez Alvarez, Carmen, Perez de la Cruz, Antonio, Molina Soria, Juan Bautista, Matos Adames, Alfredo, Garcia Luna, Pedro Pablo, Burgos Pelaez, Rosa, Escudero Alvarez, Elena, Garcia Almeida, Jose Manuel, Garcia de Lorenzo, Abelardo et al.
DOI: 10.3305/nh.2015.32.2.9324

Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors.

PMID: 26324363
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2015
Reference: J Clin Oncol. 2015 Oct 20;33(30):3401-8. doi: 10.1200/JCO.2014.60.7341. Epub 2015 Aug 31.
Impact factor: 18.428
Publication type: Paper in international publication
Authors: Zhong, Bob, Platero, Suso J, Smit, Johan W, Stuyckens, Kim, Chatterjee-Kishore, Moitreyee, Rodon, Jordi, Peddareddigari, Vijay, Luo, Feng R, Soria, Jean-Charles, Gazzah, Anas et al.
DOI: 10.1200/JCO.2014.60.7341

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer.

PMID: 25989270
Journal: BRITISH JOURNAL OF CANCER
Year: 2015
Reference: Br J Cancer. 2015 Jun 9;112(12):1874-81. doi: 10.1038/bjc.2015.144. Epub 2015 May 19.
Impact factor: 4.836
Publication type: Paper in international publication
Authors: Macarulla, T, Cervantes, A, Tabernero, J, Rosello, S, Van Cutsem, E, Tejpar, S, Prenen, H, Martinelli, E, Troiani, T, Laffranchi, B et al.
DOI: 10.1038/bjc.2015.144

Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

PMID: 25840972
Journal: CLINICAL CANCER RESEARCH
Year: 2015
Reference: Clin Cancer Res. 2015 Jul 15;21(14):3160-9. doi: 10.1158/1078-0432.CCR-14-3262. Epub 2015 Apr 3.
Impact factor: 8.722
Publication type: Clinical Trials
Authors: Awan, Farrukh T, Jiang, Jason, Brown, Jennifer R, Davids, Matthew S, Rodon, Jordi, Abrisqueta, Pau, Kasar, Siddha N, Lager, Joanne, Egile, Coumaran et al.
DOI: 10.1158/1078-0432.CCR-14-3262

Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02.

PMID: 25491381
Journal: CANCER CHEMOTHERAPY AND PHARMACOLOGY
Year: 2015
Reference: Cancer Chemother Pharmacol. 2015 Feb;75(2):319-24. doi: 10.1007/s00280-014-2641-3. Epub 2014 Dec 10.
Impact factor: 2.769
Publication type: Clinical Trials
Authors: Manzano, J L, Galan, M, Alsina, M, Yuste Izquierdo, A L, Lopez, C, Diaz-Rubio, E, Conde, V, Reboredo, M, Cano, M T, Pachon, V et al.
DOI: 10.1007/s00280-014-2641-3

Phase I/II dose-escalation study of PI3K inhibitors pilaralisib or voxtalisib in combination with letrozole in patients with hormone-receptor-positive and HER2-negative metastatic breast cancer refractory to a non-steroidal aromatase inhibitor.

PMID: 26497877
Journal: BREAST CANCER RESEARCH AND TREATMENT
Year: 2015
Reference: Breast Cancer Res Treat. 2015 Nov;154(2):287-97. doi: 10.1007/s10549-015-3615-9. Epub 2015 Oct 24.
Impact factor: 3.94
Publication type: Paper in international publication
Authors: Blackwell, Kimberly, Burris, Howard, Gomez, Patricia, Lynn Henry, N, Isakoff, Steven, Campana, Frank, Gao, Lei, Jiang, Jason, Mace, Sandrine, Tolaney, Sara M et al.
DOI: 10.1007/s10549-015-3615-9

Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane.

PMID: 25605862
Journal: JOURNAL OF CLINICAL ONCOLOGY
Year: 2015
Reference: J Clin Oncol. 2015 Feb 20;33(6):594-601. doi: 10.1200/JCO.2013.52.4892. Epub 2015 Jan 20.
Impact factor: 18.428
Publication type: Paper in international publication
Authors: Kaufman, Peter A, Awada, Ahmad, Twelves, Chris, Yelle, Louise, Perez, Edith A, Velikova, Galina, Olivo, Martin S, He, Yi, Dutcus, Corina E, Cortes, Javier et al.
DOI: 10.1200/JCO.2013.52.4892

Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer.

PMID: 25925990
Journal: GYNECOLOGIC ONCOLOGY
Year: 2015
Reference: Gynecol Oncol. 2015 Jul;138(1):18-23. doi: 10.1016/j.ygyno.2015.04.026. Epub 2015 Apr 26.
Impact factor: 3.774
Publication type: Paper in international publication
Authors: McMeekin, Scott, Dizon, Don, Barter, James, Scambia, Giovanni, Manzyuk, Lyudmila, Lisyanskaya, Alla, Oaknin, Ana, Ringuette, Sarah, Mukhopadhyay, Pralay, Rosenberg, Julie et al.
DOI: 10.1016/j.ygyno.2015.04.026

Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial.

PMID: 26673577
Journal: Trials
Year: 2015
Reference: Trials. 2015 Dec 16;16:575. doi: 10.1186/s13063-015-1101-7.
Impact factor: 1.731
Publication type: Clinical Trials
Authors: Harbeck, Nadia, Barton, Debora, Renschler, Markus F, Beck, Robert M, Yardley, Denise A, Brufsky, Adam, Coleman, Robert E, Conte, Pierfranco F, Cortes, Javier, Gluck, Stefan et al.
DOI: 10.1186/s13063-015-1101-7

Phenotype consequences of myophosphorylase dysfunction: insights from the McArdle mouse model.

PMID: 25873271
Journal: JOURNAL OF PHYSIOLOGY-LONDON
Year: 2015
Reference: J Physiol. 2015 Jun 15;593(12):2693-706. doi: 10.1113/JP270085. Epub 2015 May 18.
Impact factor: 5.037
Publication type: Paper in international publication
Authors: Blanco-Grau, Albert, Lucia, Alejandro, Martin, Miguel Angel, Arenas, Joaquin, Marti, Ramon, Andreu, Antoni L, Pinos, Tomas, de Luna, Noemi, Brull, Astrid et al.
DOI: 10.1113/JP270085

Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry.

PMID: 25038238
Journal: ANNALS OF THE RHEUMATIC DISEASES
Year: 2015
Reference: Ann Rheum Dis. 2015 Nov;74(11):2043-9. doi: 10.1136/annrheumdis-2013-204991. Epub 2014 Jul 18.
Impact factor: 10.377
Publication type: Paper in international publication
Authors: Bader-Meunier, B, Levy, R, Gerard, L, Kuemmerle-Deschner, J, Lachmann, H J, Kone-Paut, I, Cantarini, L, Woo, P, Naselli, A, Ozen, S et al.
DOI: 10.1136/annrheumdis-2013-204991

Phone and Video-Based Modalities of Central Blinded Adjudication of Modified Rankin Scores in an Endovascular Stroke Trial.

PMID: 26542697
Journal: STROKE
Year: 2015
Reference: Stroke. 2015 Dec;46(12):3405-10. doi: 10.1161/STROKEAHA.115.010909. Epub 2015 Nov 5.
Impact factor: 5.723
Publication type: Paper in international publication
Authors: Lopez-Cancio, Elena, Salvat, Merce, Cerda, Neus, Jimenez, Marta, Codas, Javier, Llull, Laura, Boned, Sandra, Cano, Luis M, Lara, Blanca, Molina, Carlos et al.
DOI: 10.1161/STROKEAHA.115.010909

Phospholipid profile of amniotic fluid in ovine model of congenital diaphragmatic hernia (CDH): the effect of fetal tracheal occlusion.

PMID: 25625961
Journal: JOURNAL OF PROTEOME RESEARCH
Year: 2015
Reference: J Proteome Res. 2015 Mar 6;14(3):1465-71. doi: 10.1021/pr501120x. Epub 2015 Feb 11.
Impact factor: 4.245
Publication type: Paper in international publication
Authors: Peiro, Jose Luis, Mimmi, Maria Chiara, Ballico, Maurizio, Amoroso, Francesco, Calcaterra, Valeria, Marotta, Mario, Pelizzo, Gloria et al.
DOI: 10.1021/pr501120x

Phosphomannomutase deficiency (PMM2-CDG): ataxia and cerebellar assessment.

PMID: 26502900
Journal: Orphanet Journal of Rare Diseases
Year: 2015
Reference: Orphanet J Rare Dis. 2015 Oct 26;10:138. doi: 10.1186/s13023-015-0358-y.
Impact factor: 3.358
Publication type: Paper in international publication
Authors: Serrano, Mercedes, de Diego, Victor, Muchart, Jordi, Cuadras, Daniel, Felipe, Ana, Macaya, Alfons, Velazquez, Ramon, Poo, M Pilar, Fons, Carmen, O'Callaghan, M Mar et al.
DOI: 10.1186/s13023-015-0358-y

Phosphorylation of eIF4E Confers Resistance to Cellular Stress and DNA-Damaging Agents through an Interaction with 4E-T: A Rationale for Novel Therapeutic Approaches.

PMID: 25923732
Journal: PLoS One
Year: 2015
Reference: PLoS One. 2015 Apr 29;10(4):e0123352. doi: 10.1371/journal.pone.0123352. eCollection 2015.
Impact factor: 3.234
Publication type: Paper in international publication
Authors: Martinez, Alba, Sese, Marta, Losa, Javier Hernandez, Robichaud, Nathaniel, Sonenberg, Nahum, Aasen, Trond, Ramon Y Cajal, Santiago et al.
DOI: 10.1371/journal.pone.0123352

Publications